國家衛生研究院 NHRI:Item 3990099045/11211
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 854114      在线人数 : 1485
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11211


    题名: Optimization of furanopyrimidine-based kinase inhibitors: Identification of a BTK kinase inhibitor for the treatment of B cell lymphoma
    作者: Wang, WC;Hsu, YC;Shiao, HY;Hung, HC;Kuo, CC;Lee, JC;Hsu, TA;Hsieh, HP
    贡献者: Institute of Biotechnology and Pharmaceutical Research
    摘要: According to the statistics from Ministry of Health and Welfare in Taiwan, non-Hodgkin's lymphoma is ranked as number nine on leading cause of cancer death toward both male and female people. In Taiwan, 85% non-Hodgkin's lymphoma patients belong to B cell lymphoma patients. In general, these kinds of blood diseases were treated by traditional chemotherapy or radiation therapy, but the results exert poor treatment effectiveness. In these years, scientists reported Bruton’s tyrosine kinase (BTK) is a key component in the B-cell receptor signal pathway regulating survival, activation, proliferation, and differentiation of B cells. Several studies demonstrated that BTK is overexpressed in several B cell lymphomas and BTK inhibitors may be useful in lymphoma patients. Hence, BTK inhibitors may constitute an exciting new generation of treatments for B cell lymphomas. In our effort to develop novel BTK inhibitors, BPRBK0005 was first identified as a BTK lead through screening our in house synthesized kinase inhibitors. We next sought in silico means to proceed further lead optimizations. A new series of furanopyrimidinecontaining derivatives were synthesized and evaluated against BTK enzyme- and cellbased assays. Among these, BPRBK0169 reveal excellent BTK inhibition with an IC50 value of 10 nM, calcium flux inhibition with an IC50 value of 11 nM, as well as up to 38-fold more potent antiproliferation in Ramos lymphoma cell line than the leading clinical drug, ibrutinib. Accordingly, it is considered a highly promising candidate for further development.
    日期: 2015-08
    關聯: Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 180.
    Link to: https://www.acs.org/content/acs/en/meetings/national-meeting/about/meetings-archive.html
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000432475701334
    显示于类别:[謝興邦] 會議論文/會議摘要
    [李靜琪] 會議論文/會議摘要
    [郭靜娟] 會議論文/會議摘要
    [王文傑] 會議論文/會議摘要

    文件中的档案:

    档案 大小格式浏览次数
    ISI000432475701334.pdf89KbAdobe PDF1113检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈